NCT01782664已完成2 期
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)
研究概览
简要总结
A multi-centre, randomised, dose ranging study to evaluate the safety and clinical efficacy of GSK2586184 in patients with chronic plaque psoriasis.
There will be 2 study cohorts (Cohorts A and B). Cohort A is the main study cohort, and this part of the study will be randomised, double-blind and placebo-controlled. Fifty-six subjects will be randomised in Cohort A: 14 subjects in each treatment group: 100 mg, 200 mg or 400 mg GSK2586184, or placebo. Cohort B is an exploratory, open-label investigation of the effect of 400 mg GSK2586184 on inflammatory gene expression in the skin and whole blood, and GSK2586184 concentrations in the skin. A maximum of 8 subjects will be included, and all subjects will take 400 mg GSK2586184.
In both Cohorts A and B, study medication will be administered orally (as tablets), twice daily, for up to 12 weeks.
Each subject will have 7 out-patient visits: Screening; Baseline & Start of treatment; Week 2; Week 4; Week 8; Week 12; and Follow-up (Week 16)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Otherwise healthy subjects with a diagnosis of moderate to severe plaque psoriasis defined by the following criteria:
- •Diagnosed for at least 12 months before the first dose of study medication
- •Psoriasis plaques cover >=10% of body surface area.
- •PASI score of >=12, and PGA score of>=3, and suitable for systemic or light therapy.
- •Male or female, between 18 and 75 years of age inclusive.
- •Female subjects of childbearing potential must agree to avoid pregnancy and male subjects must agree to avoid female partners becoming pregnant.
- •Subjects must agree to use ultra violet (UV) light protection.
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
排除标准
- •Unable to refrain from the use of the following prescription and non-prescription drugs from the following periods before the first dose of study medication until completion of the follow-up visit:
- •12 weeks: alefacept, ustekinumab, adalimumab, etanercept, infliximab, or certolizumab pegol
- •4 weeks or 5 half-lives, whichever is longer:
- •systemic medications for other medical conditions that are known to affect psoriasis, including but not limited to oral corticosteroids, cyclosporine, methotrexate, lithium, and beta-adrenergic blockers
- •7 days or 5 half-lives, whichever is longer:
- •statins and other OATP and BCRP sensitive substrates (e.g. rapaglinide)
- •any agent known to be a substrate of MATE1 and MATE2-K, which undergoes significant renal secretion (e.g. cimetidine)
- •3 weeks or 5 half-lives, whichever is longer:
- •any agent known to be a strong CYP3A4 inhibitor or inducer
- •2 weeks: topical therapies that are known to affect psoriasis, including but not limited to corticosteroids, retinoids, vitamin D derivatives, tar and anthralin
- •Other medications (including vitamins, herbal and dietary supplements) will be considered on a case-by-case basis, and will be allowed if in the opinion of the investigator the medication will not interfere with the study procedures or compromise subject safety.
- •Phototherapy within 4 weeks before the first dose of study medication.
- •A live vaccination within 4 weeks before the first dose of study medication, or a live vaccination planned during the course of the study (until completion of the follow-up visit).
- •A major organ transplant (e.g. heart, lung, kidney, liver) or haematopoietic stem cell/marrow transplant.
- •Significant unstable or uncontrolled acute or chronic disease unrelated to psoriasis (i.e. cardiovascular including uncontrolled hypertension, hypercholesterolemia, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk.
- •A planned surgical procedure that, in the opinion of the investigator, makes the subject unsuitable for the study.
- •A history of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
- •Acute or chronic infections, as follows:
- •Known previous or active infection with Mycobacterium Tuberculosis
- •Currently on any suppressive therapy for a chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria).
- •Hospitalisation for treatment of infection within 60 days before first dose.
- •Use of parenteral (IV or intramuscular) antibiotics (antibacterials, antivirals, antifungals, or antiparasitic agents) within 60 days before first dose.
- •Unable to refrain from the consumption of grapefruit or grapefruit juice from 3 weeks before the first dose of study medication until 2 weeks after the last dose of study medication.
- •History of sensitivity to any components of the study medications, or a history of drug or other allergy that, in the opinion of the investigator, contraindicates their participation.
- •Serologic evidence of Hepatitis B (HB) infection based on the results of testing for HBsAg, anti-HBc antibody as follows: subjects positive for HBsAg are excluded; and subjects positive for anti-HBc antibody (regardless of anti-HBs antibody status) are excluded.
- •Positive test for Hepatitis C antibody confirmed sample with a Hepatitis C RIBA immunoblot assay or equivalent. Subjects who are positive for Hepatitis C antibody, but negative when the Hepatitis C RIBA immunoblot assay or equivalent test is performed will be eligible to participate. Subjects who are positive for Hepatitis C antibody and have a positive or indeterminate result when the Hepatitis C RIBA immunoblot assay or equivalent test is performed will not be eligible to participate.
- •A positive test for HIV antibody.
- •Pregnant females as determined by a positive serum hCG test at screening, or a positive urine hCG test pre-dose on Day
- •Lactating females.
- •Haemoglobin <11 g/dL, haematocrit <30%, WBC count (absolute) <3 × 10^9/L, neutrophils <1.5 × 10^9/L, platelets <100 × 10^9/L, lymphocytes <1 x 10^9/L.
- •Current or history of renal disease, or estimated creatinine clearance <60 mL/min/1.73m^2 or serum creatinine >1.5 ULN.
- •Single QTc > 450 msec; or QTc > 480 msec in subjects with Bundle Branch Block.
- •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •ALT > 2xULN; alkaline phosphatase and bilirubin ≥ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
- •The subject has participated in a clinical trial and has received an investigational product within 3 months before the first dose of study medication, or plans to take part in another clinical trial at the same time as participating in this clinical trial.
研究组 & 干预措施
100 mg GSK2586184
Experimental
Subjects will be randomized to 100 mg GSK2586184 twice daily for up to 84 days
干预措施: 100 mg GSK2586184 (Drug)
200 mg GSK2586184
Experimental
Subjects will be randomized to 200 mg GSK2586184 twice daily for up to 84 days
干预措施: 200 mg GSK2586184 (Drug)
400 mg GSK2586184
Experimental
Subjects will be randomized to 400 mg GSK2586184 twice daily for up to 84 days
干预措施: 400 mg GSK2586184 (Drug)
Placebo
Placebo Comparator
Subjects will be randomized to receive Placebo twice daily for up to 84 days
干预措施: Placebo (Drug)
400 mg GSK2586184 (Cohort B)
Experimental
Subjects will take 400 mg GSK2586184 twice daily for up to 84 days
干预措施: 400 mg GSK2586184 (Drug)
结局指标
主要结局
Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)
时间窗: Baseline and Week 12
PASI score was determined by evaluation of BSA covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline=Day 1. Percentage of participants who achieved \>= 75% improvement from Baseline was reported with LOCF analysis.
次要结局
- Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)(From Baseline (Day 1) until the Follow-up visit (Day 112))
- Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study(From Baseline (Day 1) until the Follow-up visit (Day 112))
- Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study(From Baseline (Day 1) until the Follow-up visit (Day 112))
- Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12(From Baseline (Day 1) until Week 12)
- Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12(From Baseline (Day 1) until Week 12)
- Itch VAS Scores at Week 2, 4, 8 and 12(Week 2, 4, 8 and 12)
- PASI Score at Week 2, 4, 8 and 12(Week 2, 4, 8 and 12)
- Time to PGA Score of 'Clear' (0) or 'Almost Clear' (1)(From Baseline (Day 1) until Week 12)
- Population Pharmacokinetic (PK) Derived Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Time of the Last Measureable Concentration (AUC(0-tau) of GSK2586184(Baseline (pre-dose), Day 14 (2 to 3 hour and 3 to 4 hour post-dose), Day 28 (4 to 6 hour and 6 to 8 hour post-dose), Day 56 (at anytime during clinical visit), Day 84 (1 sample to be taken at anytime during clinical visit))
- Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study(From BL (Day 1) until the Follow-up visit (Day 112))
- Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study(From Baseline (Day 1) until the follow-up visit (Day 112))
- Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12(Weeks 2, 4, 8 and 12)
- Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12(Weeks 2, 4, 8 and 12)
- Time to PASI 75(From Baseline (Day 1) until Week 12)
- Change From Baseline in Body Temperature(From Baseline (Day 1) until Week 16)
- Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12(From Baseline (Day 1) until Week 12)
- Clearance of GSK2586184(Baseline (pre-dose), Day 14 (2 to 3 hour and 3 to 4 hour post-dose), Day 28 (4 to 6 hour and 6 to 8 hour post-dose), Day 56 (at anytime during clinical visit), Day 84 (1 sample to be taken at anytime during clinical visit))
- Steady State Volume of Distribution (Vss) of GSK2586184(Baseline (pre-dose), Day 14 (2 to 3 hour and 3 to 4 hour post-dose), Day 28 (4 to 6 hour and 6 to 8 hour post-dose), Day 56 (at anytime during clinical visit), Day 84 (1 sample to be taken at anytime during clinical visit))
- Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings(From Baseline (Day 1) until the Follow-up visit (Day 112))
- Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12(Baseline and Week 12)
- Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12(Baseline (pre-dose) and Weeks 2, 4, 8 and 12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT00676052GlaxoSmithKline576
已完成
2 期
3 Month PHI PAD PoM StudyVascular Disease, PeripheralNCT02135848GlaxoSmithKline46
已完成
2 期
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary CholangitisCholestasisNCT02966834GlaxoSmithKline147
已完成
2 期
MDD POC Study GSK372475 Subjects Depressive DiseaseDepressive DisorderNCT00420641GlaxoSmithKline492
已完成
2 期
A Study Of New Medicine (GSK 372475) For The Treatment Of DepressionDepressive DisorderNCT00448058GlaxoSmithKline396